CRDF

Cardiff Oncology, Inc. [CRDF] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CRDF Stock Summary

Top CRDF Correlated Resources

CRDF


Top 10 Correlated ETFs

CRDF


Top 10 Correlated Stocks

CRDF


In the News

04:05 29 Mar 2024 CRDF

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5

You get what you pay for and that includes stocks under $5. Yeah, I might be starting off on a negative foot but here's the deal: most securities that are priced this low are that way for a reason.

08:56 29 Mar 2024 CRDF

Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

09:51 29 Mar 2024 CRDF

Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

09:11 29 Mar 2024 CRDF

Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?

Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

07:37 29 Mar 2024 CRDF

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.

01:01 29 Mar 2024 CRDF

What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?

Does Cardiff Oncology (CRDF) have what it takes to be a top stock pick for momentum investors? Let's find out.

08:40 29 Mar 2024 CRDF

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.20 per share a year ago.

08:06 29 Mar 2024 CRDF

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET

09:11 29 Mar 2024 CRDF

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Mark Erlander - CEO Jamie Levine - CFO Conference Call Participants Mark Frahm - TD Cowen Joe Catanzaro - Piper Sandler Companies Andy Hsieh - William Blair & Company Operator Welcome to the Cardiff Oncology third-quarter 2023 financial results and corporate update conference call. [Operator Instructions].

11:19 29 Mar 2024 CRDF

Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Cardiff Oncology (CRDF) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

CRDF Financial details

Company Rating
Neutral
Market Cap
261.36M
Income
-40.61M
Revenue
488K
Book val./share
1.56
Cash/share
1.67
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.01
Forward P/E
-5.09
PEG
-3.46
P/S
171.91
P/B
1.02
P/C
3.2
P/FCF
-2.34
Quick Ratio
9.04
Current Ratio
9.3
Debt / Equity
0.03
LT Debt / Equity
0.02
-
-
EPS (TTM)
-0.91
EPS next Y
-1.05
EPS next Q
-0.24
EPS this Y
8.14%
EPS next Y
15.75%
EPS next 5Y
150%
EPS last 5Y
-19.2%
Revenue last 5Y
14.78%
Revenue Q/Q
10.64%
EPS Q/Q
-4.55%
-
-
-
-
SMA20
189.25%
SMA50
226.06%
SMA100
407.55%
Inst Own
9.49%
Inst Trans
0.72%
ROA
-44%
ROE
-43%
ROC
-0.56%
Gross Margin
100%
Oper. Margin
-9668%
Profit Margin
-8538%
Payout
-1%
Shs Outstand
44.68M
Shs Float
41.07M
-
-
-
-
Target Price
-
52W Range
0.94-6.11
52W High
-
52W Low
-
RSI
64.24
Rel Volume
0.55
Avg Volume
1.56M
Volume
864.48K
Perf Week
9.65%
Perf Month
206.9%
Perf Quarter
341.32%
Perf Half Y
229.63%
-
-
-
-
Beta
1.713
-
-
Volatility
0.34%, 1.58%
Prev Close
-7.13%
Price
5.34
Change
-1.84%

CRDF Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.040.020.010.010.01
Net income per share
-2.7-0.92-0.71-0.86-0.93
Operating cash flow per share
-2.22-0.78-0.59-0.78-0.69
Free cash flow per share
-2.23-0.79-0.6-0.8-0.7
Cash per share
1.716.273.612.411.67
Book value per share
1.226.143.62.441.56
Tangible book value per share
1.226.143.62.441.56
Share holders equity per share
1.226.143.62.441.56
Interest debt per share
0.290.040.080.10.05
Market cap
7.41M375.54M234.57M61.04M66.12M
Enterprise value
-1.06M245.42M225.75M47.41M46.62M
P/E ratio
-0.46-19.48-8.46-1.63-1.6
Price to sales ratio
30.241.03K653.4158.13135.5
POCF ratio
-0.56-23.02-10.18-1.8-2.14
PFCF ratio
-0.56-22.72-10.09-1.76-2.1
P/B Ratio
1.012.931.670.570.95
PTB ratio
1.012.931.670.570.95
EV to sales
-4.33670.57628.82122.8295.52
Enterprise value over EBITDA
0.07-13.22-7.87-1.2-1.04
EV to operating cash flow
0.08-15.04-9.8-1.4-1.51
EV to free cash flow
0.08-14.85-9.71-1.37-1.48
Earnings yield
-2.18-0.05-0.12-0.61-0.63
Free cash flow yield
-1.8-0.04-0.1-0.57-0.48
Debt to equity
0.240.010.020.030.03
Debt to assets
0.130.010.020.020.03
Net debt to EBITDA
0.527.010.310.340.43
Current ratio
2.3721.7922.2814.257.41
Interest coverage
0-12.56K0-25.240
Income quality
0.810.850.810.870.75
Dividend Yield
3.270.0600.010
Payout ratio
-1.5-1.260-0.010
Sales general and administrative to revenue
23.5122.4532.9734.1526.73
Research and developement to revenue
45.5630.748.470.2367.33
Intangibles to total assets
00000
Capex to operating cash flow
0.010.010.010.030.02
Capex to revenue
-0.28-0.58-0.57-2.31-1.19
Capex to depreciation
-0.14-0.45-0.45-3.78-1.46
Stock based compensation to revenue
3.614.829.0111.039.24
Graham number
8.6311.37.596.875.71
ROIC
-1.52-0.15-0.19-0.35-0.62
Return on tangible assets
-1.23-0.14-0.19-0.32-0.51
Graham Net
0.775.973.382.21.41
Working capital
6.57M127.24M139.57M103.48M66.97M
Tangible asset value
7.31M128.16M140.42M106.34M69.74M
Net current asset value
5.58M126.79M137M101.44M65.51M
Invested capital
0.240.010.020.030.03
Average receivables
186K262.23K427.73K653K529.5K
Average payables
660.5K1.01M1.4M1.7M1.96M
Average inventory
0.50.5000
Days sales outstanding
303.92319.59543.94729.05215.41
Days payables outstanding
21.4544.381.05K3.57K1.8K
Days of inventory on hand
00000
Receivables turnover
1.21.140.670.51.69
Payables turnover
17.028.220.350.10.2
Inventory turnover
11.16M0000
ROE
-2.21-0.15-0.2-0.35-0.59
Capex per share
-0.01-0.01-0.01-0.02-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.18-0.23-0.25-0.22-0.21
Operating cash flow per share
-0.22-0.19-0.16-0.18-0.16
Free cash flow per share
-0.22-0.19-0.17-0.19-0.16
Cash per share
2.412.1721.821.67
Book value per share
2.442.161.941.741.56
Tangible book value per share
2.442.161.941.741.56
Share holders equity per share
2.442.161.941.741.56
Interest debt per share
0.080.040.050.050.07
Market cap
61.04M73.72M65.6M62.1M66.12M
Enterprise value
47.41M61.28M48.66M49.16M46.62M
P/E ratio
-1.91-1.77-1.47-1.6-1.77
Price to sales ratio
476.88888.16607.38440.43423.86
POCF ratio
-6.5-8.51-9.2-7.8-9.26
PFCF ratio
-6.45-8.51-8.88-7.51-9.25
P/B Ratio
0.570.760.760.80.95
PTB ratio
0.570.760.760.80.95
EV to sales
370.38738.28450.6348.67298.82
Enterprise value over EBITDA
-5.09-5.12-4.02-4.59-4.56
EV to operating cash flow
-5.05-7.08-6.82-6.18-6.53
EV to free cash flow
-5.01-7.07-6.59-5.94-6.52
Earnings yield
-0.13-0.14-0.17-0.16-0.14
Free cash flow yield
-0.16-0.12-0.11-0.13-0.11
Debt to equity
0.030.030.030.030.03
Debt to assets
0.020.020.020.030.03
Net debt to EBITDA
1.461.041.41.211.91
Current ratio
14.2512.4910.169.37.41
Interest coverage
-12.6914.5400-12.46
Income quality
1.080.770.640.820.76
Dividend Yield
0.010000
Payout ratio
-0.050000
Sales general and administrative to revenue
24.0537.1439.7820.8417.47
Research and developement to revenue
50.33109.0674.2656.8949.76
Intangibles to total assets
00000
Capex to operating cash flow
0.0100.040.040
Capex to revenue
-0.59-0.1-2.32-2.23-0.05
Capex to depreciation
-0.87-0.09-2.56-2.94-0.08
Stock based compensation to revenue
7.9112.8214.646.775.83
Graham number
3.173.363.32.922.71
ROIC
-0.08-0.11-0.12-0.12-0.19
Return on tangible assets
-0.07-0.1-0.11-0.11-0.11
Graham Net
2.21.961.761.591.41
Working capital
103.48M93.61M83.61M74.89M66.97M
Tangible asset value
106.34M96.5M86.58M77.83M69.74M
Net current asset value
101.44M91.71M81.86M73.28M65.51M
Invested capital
0.030.030.030.030.03
Average receivables
710.5K723.5K418.5K179.5K243K
Average payables
1.69M2.44M2.93M2.56M2.07M
Average inventory
0.500.50.50
Days sales outstanding
542.11733.01134.17126.38166.15
Days payables outstanding
3.52K2.91K2.7K1.83K1.72K
Days of inventory on hand
00000
Receivables turnover
0.170.120.670.710.54
Payables turnover
0.030.030.030.050.05
Inventory turnover
0098K00
ROE
-0.08-0.11-0.13-0.13-0.13
Capex per share
00-0.01-0.010

CRDF Frequently Asked Questions

What is Cardiff Oncology, Inc. stock symbol ?

Cardiff Oncology, Inc. is a US stock , located in San diego of Ca and trading under the symbol CRDF

What is Cardiff Oncology, Inc. stock quote today ?

Cardiff Oncology, Inc. stock price is $5.34 today.

Is Cardiff Oncology, Inc. stock public?

Yes, Cardiff Oncology, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap